The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases

Cellular and Molecular Life Sciences

Volumn 67, Issue 15, 2010, Pages 2533-2550

  Sesarman, Alina ^a   Vidarsson, Gestur ^b   Sitaru, Cassian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

Autoantibody; Autoimmunity; Engineered IgG; IgG homeostasis; Immunoapheresis; Therapeutic IgG

Indexed keywords

ABDEGS; ANTIINFLAMMATORY AGENT; AUTOANTIBODY; CORTICOSTEROID; DEXAMETHASONE; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LEVOTHYROXINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1G3; RECOMBINANT FC FUSION PROTEIN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ANTIBODY; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN FC FRAGMENT;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BINDING AFFINITY; CLINICAL EFFECTIVENESS; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; INFLAMMATORY DISEASE; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; NONHUMAN; PATIENT SAFETY; PEMPHIGUS VULGARIS; POLYNEUROPATHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; TISSUE INJURY; ANIMAL; BLOOD; HALF LIFE TIME; IMMUNOLOGY; METABOLISM; MOUSE; RAT; SERUM;

ANIMALS; ANTIBODIES; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOGLOBULIN FC FRAGMENTS; MICE; RATS; RECEPTORS, FC; SERUM;

EID: 77954680599     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0318-6     Document Type: Review

References (202)

1. Sinha AA, Lopez MT, McDevitt HO (1990) Autoimmune diseases: the failure of self tolerance. Science 248:1380-1388
2. Bach J (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911-920 FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104:903-911
3. Drachman DB (1990) How to recognize an antibody-mediated autoimmune disease: criteria. Res Publ Assoc Res Nerv Ment Dis 68:183-186
4. Rose NR, Bona C (1993) Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 14:426-430
5. Stassi G, De Maria R (2002) Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol 2:195-204
6. Irani S, Lang B (2008) Autoantibody-mediated disorders of the central nervous system. Autoimmunity 41:55-65
7. Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116:2843-2854
8. Mihai S, Sitaru C (2007) Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 11:462-481
9. Edwards JCW, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6:394-403
10. Martin F, Chan AC (2006) B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24:467-496
11. Hershko AY, Naparstek Y (2005) Removal of pathogenic autoantibodies by immunoadsorption. Ann NY Acad Sci 1051:635-646
12. Manz RA, Hauser A, Hiepe F, Radbruch A (2005) Maintenance of serum antibody levels. Annu Rev Immunol 23:367-386
13. Jefferis R, Lund J, Pound JD (1998) IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 163:59-76
14. Edelman GM (1991) Antibody structure and molecular immunology. Scand J Immunol 34:1-22
15. Yamaguchi Y, Kim H, Kato K, Masuda K, Shimada I, Arata Y (1995) Proteolytic fragmentation with high specificity of mouse immunoglobulin G. Mapping of proteolytic cleavage sites in the hinge region. J Immunol Methods 181:259-267
16. Elkon K, Casali P (2008) Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 4:491-498
17. Jankovic M, Casellas R, Yannoutsos N, Wardemann H, Nussenzweig MC (2004) RAGs and regulation of autoantibodies. Annu Rev Immunol 22:485-501
18. Nimmerjahn F, Ravetch JV (2008) Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 8:34-47
19. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346-349
20. van Sorge NM, van der Pol W, van de Winkel JGJ (2003) Fc gammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61:189-202
21. Ghetie V, Ward ES (2000) Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18:739-766
22. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725
23. Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG (2006) FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 108:3573-3579
24. Rodewald R, Kraehenbuhl JP (1984) Receptor-mediated transport of IgG. J Cell Biol 99:159s-164s
25. Simister NE, Rees AR (1985) Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 15:733-738
26. Simister NE, Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337:184-187
27. Bjorkman PJ, Parham P (1990) Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 59:253-288
28. Wernick NLB, Haucke V, Simister NE (2005) Recognition of the tryptophan-based endocytosis signal in the neonatal Fc Receptor by the mu subunit of adaptor protein-2. J Biol Chem 280:7309-7316
29. Newton EE, Wu Z, Simister NE (2005) Characterization of basolateral-targeting signals in the neonatal Fc receptor. J Cell Sci 118:2461-2469
30. Ahouse JJ, Hagerman CL, Mittal P, Gilbert DJ, Copeland NG, Jenkins NA, Simister NE (1993) Mouse MHC class I-like Fc receptor encoded outside the MHC. J Immunol 151:6076-6088
31. Burmeister WP, Huber AH, Bjorkman PJ (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372:379-383
32. Kandil E, Noguchi M, Ishibashi T, Kasahara M (1995) Structural and phylogenetic analysis of the MHC class I-like Fc receptor gene. J Immunol 154:5907-5918
33. Story CM, Mikulska JE, Simister NE (1994) A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 180:2377-2381
34. Adamski FM, King AT, Demmer J (2000) Expression of the Fc receptor in the mammary gland during lactation in the marsupial Trichosurus vulpecula (brushtail possum). Mol Immunol 37:435-444
35. Kacskovics I, Wu Z, Simister NE, Frenyó LV, Hammarström L (2000) Cloning and characterization of the bovine MHC class I-like Fc receptor. J Immunol 164:1889-1897
36. Kacskovics I, Mayer B, Kis Z, Frenyó LV, Zhao Y, Muyldermans S, Hammarström L (2006) Cloning and characterization of the dromedary (Camelus dromedarius) neonatal Fc receptor (drFcRn). Dev Comp Immunol 30:1203-1215
37. Mayer B, Zolnai A, Frenyó LV, Jancsik V, Szentirmay Z, Hammarström L, Kacskovics I (2002) Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs. Immunology 107:288-296
38. Schnulle PM, Hurley WL (2003) Sequence and expression of the FcRn in the porcine mammary gland. Vet Immunol Immunopathol 91:227-231
39. Martin WL, West APJ, Gan L, Bjorkman PJ (2001) Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7:867-877
40. Kim JK, Tsen MF, Ghetie V, Ward ES (1994) Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol 24:542-548
41. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES (1999) Mapping the site on human IgG for binding of the MHC class I-related receptor. FcRn. Eur. J. Immunol. 29:2819-2825
42. Medesan C, Radu C, Kim JK, Ghetie V, Ward ES (1996) Localization of the site of the IgG molecule that regulates maternofetal transmission in mice. Eur J Immunol 26:2533-2536
43. Vaughn DE, Milburn CM, Penny DM, Martin WL, Johnson JL, Bjorkman PJ (1997) Identification of critical IgG binding epitopes on the neonatal Fc receptor. J Mol Biol 274:597-607
44. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 101:9763-9768
45. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, Lencer WI (1999) Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104:903-911
46. Dickinson BL, Claypool SM, D'Angelo JA, Aiken ML, Venu N, Yen EH, Wagner JS, Borawski JA, Pierce AT, Hershberg R, Blumberg RS, Lencer WI (2008) Ca2 +-dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway. Mol Biol Cell 19:414-423
47. Haymann J, Delarue F, Baud L, Sraer J (2004) Aggregated IgG bind to glomerular epithelial cells to stimulate urokinase release through an endocytosis-independent process. Nephron Exp Nephrol 98:e13-e21
48. Sakagami M, Omidi Y, Campbell L, Kandalaft LE, Morris CJ, Barar J, Gumbleton M (2006) Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung. Pharm Res 23:270-279
49. Kobayashi N, Suzuki Y, Tsuge T, Okumura K, Ra C, Tomino Y (2002) FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 282:F358-F365
50. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, Lencer WI, Blumberg RS (2004) Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20:769-783
51. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, Lencer WI (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 196:303-310
52. Tzaban S, Massol RH, Yen E, Hamman W, Frank SR, Lapierre LA, Hansen SH, Goldenring JR, Blumberg RS, Lencer WI (2009) The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol 185:673-684
53. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP (2005) Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 18:294-303
54. Bitonti AJ, Dumont JA (2006) Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 58:1106-1118
55. Yoshida M, Kobayashi K, Kuo TT, Bry L, Glickman JN, Claypool SM, Kaser A, Nagaishi T, Higgins DE, Mizoguchi E, Wakatsuki Y, Roopenian DC, Mizoguchi A, Lencer WI, Blumberg RS (2006) Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest 116:2142-2151
56. Ghetie V, Ward ES (2002) Transcytosis and catabolism of antibody. Immunol Res 25:97-113
57. Ward ES, Ober RJ (2009) Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol 103:77-115
58. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, Lencer WI, Blumberg RS (2001) MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 166:3266-3276
59. Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, Miner JH, Roopenian DC, Unanue ER, Shaw AS (2008) Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA 105:967-972
60. Mi W, Wanjie S, Lo S, Gan Z, Pickl-Herk B, Ober RJ, Ward ES (2008) Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments. J Immunol 181:7550-7561
61. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci USA 106:2788-2793
62. Kim H, Fariss RN, Zhang C, Robinson SB, Thill M, Csaky KG (2008) Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 49:2025-2029
63. Qiao S, Kobayashi K, Johansen F, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS (2008) Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 105:9337-9342
64. Brambell FW, Hemmings WA, Morris IG (1964) A theoretical model of gamma-globulin catabolism. Nature 203:1352-1354
65. Junghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516
66. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690-696
67. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE (1996) Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89:573-578
68. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170:3528-3533
69. Liu Z, Roopenian DC, Zhou X, Christianson GJ, Diaz LA, Sedmak DD, Anderson CL (1997) Beta2-microglobulin-deficient mice are resistant to bullous pemphigoid. J Exp Med 186:777-783
70. Marino M, Ruvo M, Falco SD, Fassina G (2000) Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat Biotechnol 18:735-739
71. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D (2004) The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113:1328-1333
72. Sesarman A, Sitaru AG, Olaru F, Zillikens D, Sitaru C (2008) Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J Mol Med 86:951-959
73. Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, Bitonti A (2007) Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol 178:5390-5398
74. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z (2005) Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440-3450
75. Deng R, Balthasar JP (2007) Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharm Sci 96:1625-1637
76. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759-1769
77. Raghavan M, Chen MY, Gastinel LN, Bjorkman PJ (1994) Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1:303-315
78. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755
79. Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513-533
80. Hansen RJ, Balthasar JP (2002) Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 88:898-899
81. Hansen RJ, Balthasar JP (2002) Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100:2087-2093
82. Hansen RJ, Balthasar JP (2004) IVIG effects on autoantibody elimination. Allergy 59:1124 author reply 1124
83. Hansen RJ, Balthasar JP (2004) Mechanisms of IVIG action in immune thrombocytopenic purpura. Clin Lab 50:133-140
84. Martín MG, Wu SV, Walsh JH (1993) Hormonal control of intestinal Fc receptor gene expression and immunoglobulin transport in suckling rats. J Clin Invest 91:2844-2849
85. Kim K, Fandy TE, Lee VHL, Ann DK, Borok Z, Crandall ED (2004) Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 287:L616-L622
86. Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I (2008) A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J Immunol Methods 331:39-49
87. Getman KE, Balthasar JP (2005) Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J Pharm Sci 94:718-729
88. Vaccaro C, Zhou J, Ober RJ, Ward ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23:1283-1288
89. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES (2006) Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci USA 103:18709-18714
90. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H (2006) Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 177:1129-1138
91. Mezo AR, McDonnell KA, Hehir CAT, Low SC, Palombella VJ, Stattel JM, Kamphaus GD, Fraley C, Zhang Y, Dumont JA, Bitonti AJ (2008) Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci USA 105:2337-2342
92. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL (2003) The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197:315-322
93. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573-581
94. Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484-486
95. Liu X, Ye L, Christianson GJ, Yang J, Roopenian DC, Zhu X (2007) NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences. J Immunol 179:2999-3011
96. Liu X, Ye L, Bai Y, Mojidi H, Simister NE, Zhu X (2008) Activation of the JAK/STAT-1 signaling pathway by IFNgamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG. J Immunol 181:449-463
97. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180
98. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460-470
99. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15:637-640
100. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010
101. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. doi:10.1038/nbt.1601
102. Miller SD, Turley DM, Podojil JR (2007) Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 7:665-677
103. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, Tsurushita N (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279:6213-6216
104. Dall'Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1 s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524
105. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182:7663-7671
106. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ (2007) Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 282:1709-1717
107. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134-1143
108. Scott CT (2007) Mice with a human touch. Nat Biotechnol 25:1075-1077
109. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054-1059
110. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365-368
111. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I (1996) GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Neurology 47:237-242
112. McKnight K, Jiang Y, Hart Y, Cavey A, Wroe S, Blank M, Shoenfeld Y, Vincent A, Palace J, Lang B (2005) Serum antibodies in epilepsy and seizure-associated disorders. Neurology 65:1730-1736
113. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S (2004) Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62:1177-1182
114. Hayes KC, Hull TCL, Delaney GA, Potter PJ, Sequeira KAJ, Campbell K, Popovich PG (2002) Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 19:753-761
115. Singer HS, Loiselle CR, Lee O, Minzer K, Swedo S, Grus FH (2004) Anti-basal ganglia antibodies in PANDAS. Mov Disord 19:406-415
116. Vernino S, Lennon VA (2002) Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 26:702-707
117. Barber PA, Anderson NE, Vincent A (2000) Morvan's syndrome associated with voltage-gated K + channel antibodies. Neurology 54:771-772
118. Lebar R, Lubetzki C, Vincent C, Lombrail P, Boutry JM (1986) The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 66:423-434
119. Amagai M, Klaus-Kovtun V, Stanley JR (1991) Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869-877
120. Koulu L, Kusumi A, Steinberg MS, Klaus-Kovtun V, Stanley JR (1984) Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. J Exp Med 160:1509-1518
121. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI (1981) Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 24:897-903
122. Diaz LA, Ratrie H, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, Giudice GJ (1990) Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 86:1088-1094
123. Woodley DT, Briggaman RA, ÓKeefe EJ, Inman AO, Queen LL, Gammon WR (1984) Identification of the skin basementmembrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 310:1007-1013
124. Morrison LH, Labib RS, Zone JJ, Diaz LA, Anhalt GJ (1988) Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J Clin Invest 81:2023-2026
125. Kelly SE, Bhogal BS, Wojnarowska F, Whitehead P, Leigh IM, Black MM (1990) Western blot analysis of the antigen in pemphigoid gestationis. Br J Dermatol 122:445-449
126. Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB (1992) Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 90:1628-1633
127. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR (1996) Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci USA 93:14714-14719
128. Balding SD, Prost C, Diaz LA, Bernard P, Bedane C, Aberdam D, Giudice GJ (1996) Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 106:141-146
129. Oyama N, Chan I, Neill SM, Hamada T, South AP, Wessagowit V, Wojnarowska F, D'Cruz D, Hughes GJ, Black MM, McGrath JA (2003) Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 362:118-123
130. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87:4120-4124
131. Alsalameh S, Mollenhauer J, Scheuplein F, Stöss H, Kalden JR, Burkhardt H, Burmester GR (1993) Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol 20:1419-1424
132. Kraus VB, Stabler T, Le ET, Saltarelli M, Allen NB (2003) Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis. Arthritis Rheum 48:2942-2948
133. Wakui H, Imai H, Kobayashi R, Itoh H, Notoya T, Yoshida K, Nakamoto Y, Miura AB (1988) Autoantibody against erythrocyte protein 4.1 in a patient with autoimmune hemolytic anemia. Blood 72:408-412
134. Leddy JP, Falany JL, Kissel GE, Passador ST, Rosenfeld SI (1993) Erythrocyte membrane proteins reactive with human (warm-reacting) anti-red cell autoantibodies. J Clin Invest 91:1672-1680
135. Woods VLJ, Kurata Y, Montgomery RR, Tani P, Mason D, Oh EH, McMillan R (1984) Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 64:156-160
136. Rees Smith B, McLachlan SM, Furmaniak J (1988) Autoantibodies to the thyrotropin receptor. Endocr Rev 9:106-121
137. Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, Schiaffino S (1992) Identification of alpha-and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85:1734-1742
138. Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318:1651-1657
139. Jennette JC, Hoidal JR, Falk RJ (1990) Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 75:2263-2264
140. Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG (1988) Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 263:13374-13380
141. Beck LHJ, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11-21
142. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155-163
143. Bläss S, Union A, Raymackers J, Schumann F, Ungethüm U, Müller-Steinbach S, De Keyser F, Engel JM, Burmester GR (2001) The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 44:761-771
144. Rothfield NF, Stollar BD (1967) The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complementfixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 46:1785-1794
145. Toyka KV, Brachman DB, Pestronk A, Kao I (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190:397-399
146. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306:1189-1196
147. Rock B, Martins CR, Theofilopoulos AN, Balderas RS, Anhalt GJ, Labib RS, Futamura S, Rivitti EA, Diaz LA (1989) The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 320:1463-1469
148. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480-2488
149. Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D (2005) Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 115:870-878
150. Wooley PH, Luthra HS, Singh SK, Huse AR, Stuart JM, David CS (1984) Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clin Proc 59:737-743
151. Matsumoto I, Staub A, Benoist C, Mathis D (1999) Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732-1735
152. Blank M, Cohen J, Toder V, Shoenfeld Y (1991) Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 88:3069-3073
153. Mendlovic S, Brocke S, Shoenfeld Y, Ben-Bassat M, Meshorer A, Bakimer R, Mozes E (1988) Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci USA 85:2260-2264
154. Ozaki S, Nagasawa R, Sato H, Shirai T (1984) Hybridoma autoantibodies to erythrocytes from NZB mice and the induction of hemolytic anemia. Immunol Lett 8:115-119
155. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H (2000) Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 96:2520-2527
156. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ (2004) Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113:1419-1429
157. Matsui S, Fu M, Hayase M, Katsuda S, Yamaguchi N, Teraoka K, Kurihara T, Murano H, Takekoshi N (2006) Transfer of immune components from rabbit autoimmune cardiomyopathy into severe combined immunodeficiency (SCID) mice induces cardiomyopathic changes. Autoimmunity 39:121-128
158. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955-963
159. Huang XR, Holdsworth SR, Tipping PG (1997) Th2 responses induce humorally mediated injury in experimental anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 8:1101-1108
160. Oyama N, Chan I, Neill SM, South AP, Wojnarowska F, Kawakami Y, D'Cruz D, Mepani K, Hughes GJ, Bhogal BS, Kaneko F, Black MM, McGrath JA (2004) Development of antigen-specific ELISA for circulating autoantibodies to extracellular matrix protein 1 in lichen sclerosus. J Clin Invest 113:1550-1559
161. Yaddanapudi K, Hornig M, Serge R, De Miranda J, Baghban A, Villar G, Lipkin WI (2009) Passive transfer of streptococcusinduced antibodies reproduces behavioral disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. Mol Psychiatry. doi: 10.1038/mp.2009.77
162. Roat MI, Alstadt SP, Carpenter AB, SundarRaj N, Thoft RA (1990) Antibasement membrane antibody-mediated experimental conjunctivitis. Invest Ophthalmol Vis Sci 31:168-175
163. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A (1991) Autoimmune aetiology for acquired neuromyotonia (Isaacś syndrome). Lancet 338:75-77
164. Ankeny DP, Lucin KM, Sanders VM, McGaughy VM, Popovich PG (2006) Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem 99:1073-1087
165. Patrick J, Lindstrom J (1973) Autoimmune response to acetylcholine receptor. Science 180:871-872
166. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, Kobayashi N, Mominoki K, Abe Y, Ueda N, Matsuda S (2006) Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116:1016-1024
167. Sitaru C, Chiriac MT, Mihai S, Büning J, Gebert A, Ishiko A, Zillikens D (2006) Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 177:3461-3468
168. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B (1980)
169. Blank M, Krause I, Lanir N, Vardi P, Gilburd B, Tincani A, Tomer Y, Shoenfeld Y (1995) Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell. Arthritis Rheum 38:115-122
170. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T (2000) Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 105:625-631
171. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y (1992) Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 89:1558-1563
172. Qiao B, Wu J, Chu YW, Wang Y, Wang DP, Wu HS, Xiong SD (2005) Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocytederived DNA. Rheumatology (Oxford) 44:1108-1114
173. Milich DR, Gershwin ME (1979) Murine autoimmune hemolytic anemia induced via xenogeneic erythrocyte immunization. I. Qualitative characteristics and strain variation, susceptability to induction. Clin Immunol Immunopathol 14:172-185
174. Shimojo N, Kohno Y, Yamaguchi K, Kikuoka S, Hoshioka A, Niimi H, Hirai A, Tamura Y, Saito Y, Kohn LD, Tahara K (1996) Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci USA 93:11074-11079
175. Jahns R, Boivin V, Lohse MJ (2006) Beta 1-adrenergic receptordirected autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol 112:7-14
176. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477-1483
177. Fu ML, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J (1996) A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin Immunol Immunopathol 78:203-207
178. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW (1987) Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 139:3630-3636
179. Baba A, Yoshikawa T, Iwata M, Anzai T, Nakamura I, Wainai Y, Ogawa S, Fu M (2006) Antigen-specific effects of autoantibodies against sarcolemmal Na-K-ATPase pump in immunized cardiomyopathic rabbits. Int J Cardiol 112:15-20
180. Pendergraft WF3, Preston GA, Shah RR, Tropsha A, Carter CWJ, Jennette JC, Falk RJ (2004) Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10:72-79
181. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K (2001) Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49:712-720
182. Kalluri R, Gattone VH2, Noelken ME, Hudson BG (1994) The alpha 3 chain of type IV collagen induces autoimmune Goodpasture syndrome. Proc Natl Acad Sci USA 91:6201-6205
183. Hansson AS, Heinegård D, Holmdahl R (1999) A new animal model for relapsing polychondritis, induced by cartilage matrix protein (matrilin-1). J Clin Invest 104:589-598
184. Cremer MA, Pitcock JA, Stuart JM, Kang AH, Townes AS (1981) Auricular chondritis in rats: an experimental model of relapsing polychondritis induced with type II collagen. J Exp Med 154:535-540
185. Lyons J, Ramsbottom MJ, Cross AH (2002) Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol 32:1905-1913
186. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D (1996) Organ-specific disease provoked by systemic autoimmunity. Cell 87:811-822
187. Theofilopoulos AN, Dixon FJ (1985) Murine models of systemic lupus erythematosus. Adv Immunol 37:269-390
188. Suzuka H, Yoshifusa H, Nakamura Y, Miyawaki S, Shibata Y (1993) Morphological analysis of autoimmune disease in MRLlpr, Yaa male mice with rapidly progressive systemic lupus erythematosus. Autoimmunity 14:275-282
189. Murphy ED, Roths JB (1979) A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum 22:1188-1194
190. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW (1991) Enforced BCL2 expression in Blymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88:8661-8665
191. Seery JP, Carroll JM, Cattell V, Watt FM (1997) Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med 186:1451-1459
192. Okamoto M, Murakami M, Shimizu A, Ozaki S, Tsubata T, Kumagai S, Honjo T (1992) A transgenic model of autoimmune hemolytic anemia. J Exp Med 175:71-79
193. Pöllinger B, Krishnamoorthy G, Berer K, Lassmann H, Bösl MR, Dunn R, Domingues HS, Holz A, Kurschus FC, Wekerle H (2009) Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 206:1303-1316
194. Bradley DS, Das P, Griffiths MM, Luthra HS, David CS (1998) HLA-DQ6/8 double transgenic mice develop auricular chondritis following type II collagen immunization: a model for human relapsing polychondritis. J Immunol 161:5046-5053
195. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z, Takigawa M, Seishima M, Tanaka T, Miyachi Y, Katayama I, Horiguchi Y, Miyagawa S, Furukawa F, Iwatsuki K, Hide M, Tokura Y, Furue M, Hashimoto T, Ihn H, Fujiwara S, Nishikawa T, Ogawa H, Kitajima Y, Hashimoto K (2009) A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 60:595-603
196. Law C, Marcaccio M, Tam P, Heddle N, Kelton JG (1997) High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 336:1494-1498
197. van der Meché FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 326:1123-1129
198. Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837-841
199. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256-1262
200. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T et al (1984) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2:1055-1058
201. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705-712
202. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445-449